Sep 15, 2021 / 08:30PM GMT
Operator
Greetings. Welcome to the Crinetics Pharmaceuticals, Inc. Conference Call. (Operator Instructions) Please note this conference is being recorded.
I will now turn the conference over to your host, Corey Davis. You may begin.
Corey George Davis - LifeSci Advisors, LLC - Relationship Manager
Thank you, Schmally. And thank you all for participating in today's call.
Before we start, I'd like to point out that there is a slide deck that will accompany today's presentation. It can be viewed using the webcast link provided on the Investors page of the Crinetics website. Also posted on this web page is a news release issued earlier today announcing data from the single ascending dose portion of the Phase I study evaluating CRN04777, which is the topic for today's call.
Before handing it off to the Crinetics team to talk about their newly announced data, I'd like to remind all listening that some of the information contained in the news release and on this call is covered under the safe harbor provisions of the Private Securities Litigation
Crinetics Pharmaceuticals Inc CRN04777 Phase 1 Program Results Call Transcript
Sep 16, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers